Castrate resistant prostate cancer (CRPC) is an advanced form of prostate cancer that continues to progress despite androgen deprivation therapy. According to Emily Harris et al., 2024, the number of people diagnosed with prostate cancer is projected to more than double globally over the next two decades, rising from 1.4 million in 2020 to 2.9 million by 2040. Current therapies for CRPC include androgen receptor inhibitors, chemotherapy, immunotherapy, and targeted treatments. According to the castrate resistant prostate cancer pipeline analysis by Expert Market Research, there is a growing focus on novel combination therapies, precision medicine, and advanced targeted therapeutics, driving significant market growth in the coming years.
Major companies involved in the castrate resistant prostate cancer pipeline analysis include Evopoint Biosciences Inc., FibroGen, and others.
Leading drugs currently in the pipeline include XNW5004 + Enzalutamide, FG-3246, AB001, and others.
The growth in the pipeline is driven by emerging androgen receptor inhibitors, novel immunotherapies, and targeted radioligand treatments. Increased clinical trials and strategic collaborations are expected to accelerate development and approvals in the coming years.
The Castrate Resistant Prostate Cancer Pipeline Analysis Report by Expert Market Research gives comprehensive insights into castrate resistant prostate cancer therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for castrate resistant prostate cancer. The castrate resistant prostate cancer report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The castrate resistant prostate cancer pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with castrate resistant prostate cancer treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to castrate resistant prostate cancer.
Read more about this report - Request a Free Sample
Castrate-resistant prostate cancer (CRPC) is an advanced prostate cancer type that progresses despite androgen deprivation therapy, which reduces testosterone levels. It develops when cancer cells adapt to grow and survive with minimal androgen stimulation, often resulting in aggressive disease, metastasis, and poor prognosis, making early detection and specialized treatment critical for patient outcomes.
Castrate-resistant prostate cancer treatments include androgen receptor inhibitors, chemotherapy, immunotherapy, radiopharmaceuticals, and targeted therapies designed to slow disease progression and enhance survival. In July 2024, Syncromune’s SYNC-T SV-102 therapy, granted FDA Fast Track designation, employs a personalized in situ multi-target approach, activating T cells to trigger systemic anti-tumor responses in patients with metastatic CRPC.
The pipeline is witnessing significant focus due to the rising disease burden globally. According to Emily Harris et al., 2024, prostate cancer cases are expected to increase from 1.4 million in 2020 to 2.9 million by 2040, with deaths rising from 375,000 to 700,000. As per the Centers for Disease Control and Prevention (CDC), 255,395 new cases were reported in the United States in 2022, and 33,881 deaths occurred in 2023. According to data by Prostate Cancer UK, in the United Kingdom, over 63,000 men are diagnosed annually, with Black men at higher risk. These trends highlight the urgent need for novel therapeutic options.
This section of the report covers the analysis of castrate resistant prostate cancer drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
By Drug Class
The castrate resistant prostate cancer pipeline analysis report covers 50+ drug analyses based on drug classes:
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration.
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II, with 47%, covers a major share of the total castrate resistant prostate cancer clinical trials. It is followed by phase I with 39%. Phase III contributes 10%. This robust pipeline across multiple phases indicates significant innovation and development potential, promising to expand treatment options and strengthen the market outlook for castrate resistant prostate cancer therapies.
The drug molecule categories covered under the castrate resistant prostate cancer pipeline analysis include small molecules, monoclonal antibodies, gene therapies, peptides, and polymers. The castrate resistant prostate cancer report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for castrate resistant prostate cancer. Radioligand therapies are emerging as promising treatments in the castrate resistant prostate cancer drug pipeline. For instance, 67Cu-SAR-bisPSMA, a copper-based radioligand, is under investigation in the SECuRE trial for metastatic castrate-resistant prostate cancer. It targets Prostate-Specific Membrane Antigen-expressing lesions, showing significant reductions in prostate-specific antigen levels and a favorable safety profile across multiple therapy cycles.
The EMR report for the castrate resistant prostate cancer pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed castrate resistant prostate cancer therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in castrate resistant prostate cancer clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for castrate resistant prostate cancer. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of castrate resistant prostate cancer drug candidates.
XNW5004 is a substrate-competitive, selective, small-molecule inhibitor of EZH2, exclusively developed by Evopoint Biosciences Inc. It works by targeting and inhibiting EZH2, a key enzyme involved in tumor cell proliferation and survival, thereby blocking cancer growth. This Phase Ib/II study is examining XNW5004 in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) who have failed prior hormone therapy. Administered orally as a tablet, XNW5004 is being evaluated for safety, tolerability, and anti-tumor activity, with the study estimated to be completed in July 2026.
FG-3246 is a first-in-class, fully human CD46-targeted antibody-drug conjugate (ADC) developed by FibroGen for metastatic castration-resistant prostate cancer (mCRPC). The drug combines the anti-CD46 antibody YS5 with the potent cytotoxic agent MMAE, which disrupts microtubule function, enabling selective killing of cancer cells while minimizing effects on normal tissues. FG-3246 binds to CD46, highly expressed on prostate cancer cells, and internalizes to release MMAE intracellularly. This Phase 2 study is evaluating its safety, efficacy, tolerability, and pharmacokinetics in patients post one androgen receptor signaling inhibitor and no prior taxane therapy. Administered intravenously, the study is expected to be completed by March 2028.
AB001 is an innovative Alpha Radioligand Therapy (ART) being developed by ARTBIO for patients with metastatic castration-resistant prostate cancer (mCRPC). This PSMA-targeted therapy uses Pb212 to deliver potent alpha radiation directly to prostate cancer cells, minimizing damage to surrounding healthy tissue. The ongoing Phase 1 study is examining the safety, tolerability, optimal dose, and treatment schedule of AB001 in both 177Lu-PSMA naïve and experienced patients. Administered intravenously, AB001 is undergoing dose escalation and expansion, with study completion expected by September 2033.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Castrate Resistant Prostate Cancer Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for castrate resistant prostate cancer. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into castrate resistant prostate cancer collaborations, regulatory environments, and potential growth opportunities.
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share